[Application of crossed assay design in test of drug sensitivity in vitro in combined chemotherapy of liver cancer].
A cross assay design has been carried out to test the sensitivity of drugs used in combined chemotherapy of liver cancer using human tumor cloning system in vitro. The reductive rate of the tumor clone survival was synthetically compared and statistically analysed according to calculating formula of crossed assay design. It was shown that the most effective combination of chemotherapeutic scheme could be obtained by fewer testing. Moreover, comparing the tumor response to a given drug tested by the crossed assay design with that of permutation and combinations, the results were clearly correlated (P = 0.005). We would conclude that this assay shows a good reliability and deserves practical application.
Wen
Y J
YJ
Jiangsu Province Hospital, Nanjing.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D006528:Carcinoma, Hepatocellular / Q000473:pathology*; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004354:Drug Screening Assays, Antitumor; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology*; D016685:Mitomycin / Q000008:administration & dosage; D011034:Podophyllotoxin / Q000008:administration & dosage; D014407:Tumor Cells, Cultured / Q000187:drug effects
D016685:Mitomycin; D004317:Doxorubicin; D011034:Podophyllotoxin; D002945:Cisplatin; D005472:Fluorouracil